Bluebird bio, Inc. Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 108 Posts
1 2 3 ... 7
Q2 Earnings Update: Bluebird Bio (BLUE) And Regeneron (REGN)
Article By: Rod Raynovich Thursday, August 2, 2018 11:09 PM EST
Regeneron Pharmaceuticals (REGN) soared 7% to $397 on earnings beat with adjusted EPS of $5.45. Bluebird Bio (BLUE) was up 0.79% to $156.60 despite losses and lagging revenue.
In this article: BLUE, REGN
Read
Bullish Setups To Jump Start A Hot Week
Article By: Ryan Mallory Monday, March 5, 2018 7:30 PM EST
The market is off to a hot start and these are the stocks that you will be wanting to watch.
In this article: ACN, BA, CBI, ADSK, AMAT, AMKR, ALDR, BLUE, AMC
Read
Recession Is Coming! Not.
Article By: Kevin Cook Sunday, February 25, 2018 8:20 AM EST
We can bank on stocks continuing to "bubble up" over the next year and we need only keep a vigilant eye on the inflation/rates picture and economic data for early signs of trouble (of which I see few now).
In this article: LRCX, EW, SGMO, NVDA, BABA, BLUE
Read
How Bad Was The Biotech Selloff Last Week?
Article By: Rod Raynovich Sunday, February 4, 2018 5:30 PM EST
Biotech stocks got hit with a double whammy from concerns about high prices and disruption in healthcare from reform. But biotech investors made money last year and are still in the green for 2018 even after many stocks reported earnings.
In this article: BIIB, CELG, GILD, ABBV, IBB, FBT, XBI, XLV, BLUE
Read
5 Of The Best-Performing Biotech Stocks Of 2017
Article By: Arpita Dutt Sunday, December 31, 2017 3:46 PM EST
2017 turned out to be a pretty good year for the biotech sector. The sector had been struggling due to the drug pricing controversy, mixed results, slower-than-expected new product launches, increasing competition and pipeline setbacks.
In this article: XOMA, DVAX, SGMO, ALNY, BLUE, PFE, GILD
Read
E Large Cap Stocks: Gainers And Losers In 2017
Article By: Arie Goren Saturday, December 30, 2017 12:24 PM EST
Here are the best and the worst performers among Russell 1000 stocks in 2017, and 20 stocks that have a chance to perform well in 2018, which should be another good year for investors in large cap stocks.
In this article: AN, LEN, OPK, RAD, RRC, UHS, ALNY, SBNY, EXAS, BLUE, ESNT, EVHC, SQ, UAA, OLED Also: IWB
Read
4 Biotech Stocks That More Than Doubled This Year
Article By: Zacks Investment Research Saturday, December 23, 2017 7:50 PM EST
The biotech industry has been on the comeback trail in 2017 after facing challenges including pricing pressure, rising competition, pipeline setbacks, pricing pressure, slowdown in growth of mature products and generic competition for key drugs.
In this article: JUNO, BLUE, XOMA, PBYI, PIRS, ALNY Also: CELG
Read
3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise
Article By: Arpita Dutt Monday, December 11, 2017 7:45 PM EST
At the beginning of 2017, expectations were pretty high that the pharma and biotech sector would finally see lots of mergers and acquisitions (M&As). However, that did not happen.
In this article: JUNO, BLUE, INCY Also: SNY, AMGN, JNJ, GILD
Read
Battleground: Analysts Diverge On Bluebird Bio Sickle Cell Risk
Article By: The Fly Tuesday, October 3, 2017 9:55 PM EST
Wells Fargo's analyst Jim Birchenough is recommending buying the stock on weakness as he believes his Morgan Stanley peer's analysis of the company's LentiGlobin gene therapy program for Sickle Cell Disease is flawed.
In this article: BLUE Also: GILD
Read
XBI Breaks Through On A Strong Week For Biotech
Article By: Rod Raynovich Friday, September 29, 2017 7:25 PM EST
The XBI is up 3.17% this week, 46% YTD, compared to only 1.1% WTD for the IBB. The breakthrough gains for the XBI can be attributed to strong performance of top ten holdings that are primarily mid-caps and M&A prospects.
In this article: BMY, ALNY, BMRN, IBB, AMGN, CELG, CLVS, XBI, JUNO, PBYI, SRPT, BLUE, PTCT, ABBV, FMI
Read
Biopharmaceuticals Portfolio In A Biotech Bull Market
Article By: Rod Raynovich Tuesday, September 5, 2017 11:08 PM EST
Biotech stocks broke through the July sector highs as tracked by major ETFs. However we are still about 25% off the July 2015 bubble highs but supported by good earnings fundamentals, strong technicals and potentially a seasonal strong Q4.
In this article: BMY, RHHBY, IBB, QQQ, AMGN, BIIB, GILD, XBI, ABBV, KITE, BLUE, FMI
Read
M&A Theme Continues To Boost Biotech Stocks
Article By: Rod Raynovich Wednesday, August 30, 2017 9:30 PM EST
The prospect of more M&A boosts biotech stocks for a third day this week. The large cap based IBB was up 1.87% today and 6.48% over five days to $323.76 approaching its YTD high of $327.34.
In this article: IBB, GILD, XBI, KITE, BLUE Also: BMRN, INCY, SGEN, CLVS, VRTX, AGIO, PTLA
Read
Wells Fargo Sees Little Chance Of Higher Bid For Kite Pharma
Article By: The Fly Monday, August 28, 2017 8:05 PM EST
Gilead and Kite Pharma have announced that the companies have entered into a definitive agreement pursuant to which the former will acquire the latter for $180 per share in cash.
In this article: GILD, JUNO, KITE, BLUE, CLLS
Read
Bluebird Bio Jumps After Gilead Buys Peer Kite Pharma
Article By: The Fly Monday, August 28, 2017 9:12 AM EST
Shares of Bluebird Bio are up 6% in premarket trading to $104.00 after Gilead Sciences announced an agreement to acquire Kite Pharma for $11.9B or $180 per share.
In this article: GILD, BLUE, KITE Also: CLLS, JUNO
Read
Investors Expecting Growth From Large Caps And M&A From Mid-Caps
Article By: Rod Raynovich Tuesday, August 15, 2017 9:37 PM EST
Biotech stocks in general have recovered from last week’s sell-off and remain in a monthly trend up despite a topping pattern from July. Despite weak seasonality and lack of M&A the sector is holding lows with good volume.
In this article: BMY, IBB, AMGN, CELG, GILD, XBI, XLV, ABBV, BLUE, FMI
Read
Large Cap Biopharma Earnings Boost Stocks: Update Tuesday, Aug 1
Article By: Rod Raynovich Tuesday, August 1, 2017 10:42 PM EST
Stocks were broadly higher in July after financial reports. Now that earnings are in, track technicals and potential clinical catalysts for August/September which can be weak seasonally.
In this article: BMY, MBI, MRK, RHHBY, ALXN, IBB, REGN, AMGN, CELG, GILD, XBI, ABBV, BLUE, FMI, FBIOX, FBT
Read
1 to 16 of 108 Posts
1 2 3 ... 7